Caris Life Sciences, Inc. (CAI)
NASDAQ
Closed
Aug 21, 2026
Day's Range
24.3252 wk Range
14.19Overview - CAI - Caris Life Sciences, Inc.
Key Statistics
Valuation
Enterprise Value
6.09B
P/E (Trailing)
‪2.57‬
P/E (Forward)
‪65.18‬
PEG Ratio
‪-0.02‬
Price / Sales (TTM)
‪7.03‬
Price / Book
‪11.76‬
EV / EBITDA
‪35.00‬
Profitability
Gross Margin
‪68.10%‬
Profit Margin
‪10.62%‬
Operating Margin
‪10.21%‬
Return on Assets
‪8.76%‬
Return on Equity
‪20.12%‬
Ownership
Shares Outstanding
282.58M
Float
135.51M
Short % of Shares Outstanding
‪12.82%‬
Held by Insiders
‪48.56%‬
Held by Institutions
‪58.12%‬
Price stats
50-Day Avg
‪18.08‬
200-Day Avg
‪20.99‬
Dividends
Payout Ratio
‪0.00%‬
Analyst Consensus
13 analysts
Average price target
‪$ 27.00‬Shariah Compliance
Report Date: Feb 19, 2025
Screened by Zoya using the AAOIFI methodology.
Market Cap - CAI - Caris Life Sciences, Inc.
Peers - CAI - Caris Life Sciences, Inc.
Peer Comparison
Compared with companies in Biotechnology listed on NASDAQ.
- CAINASDAQCaris Life Sciences, Inc.6.94BMarket Cap-59.89%52-week change2.57P/E (Trailing)‪10.62%‬Profit Margin
- ARGXNASDAQargenx SE American Depositary Receipt65.04BMarket Cap+34.86%52-week change39.36P/E (Trailing)‪32.26%‬Profit Margin
- ALNYNASDAQAlnylam Pharmaceuticals Inc31.60BMarket Cap-87.81%52-week change41.15P/E (Trailing)‪16.12%‬Profit Margin
- BNTXNASDAQBioNTech SE27.85BMarket Cap+0.01%52-week change160.80P/E (Trailing)‪-63.63%‬Profit Margin
- ASNDNASDAQAscendis Pharma A/S16.61BMarket Cap+24.84%52-week change20.03P/E (Trailing)‪70.84%‬Profit Margin
- BBIONASDAQBridgeBio Pharma, Inc.15.93BMarket Cap+41.98%52-week change-21.56P/E (Trailing)‪-97.02%‬Profit Margin
- BMRNNASDAQBiomarin Pharmaceutical Inc.12.91BMarket Cap+12.29%52-week change180.16P/E (Trailing)‪2.14%‬Profit Margin
Profile Summary - CAI - Caris Life Sciences, Inc.
About
Caris Life Sciences is a leading AI-driven precision medicine company that transforms healthcare through comprehensive molecular profiling and advanced machine learning. The company specializes in analyzing cancer at the molecular level by performing whole exome and whole transcriptome sequencing on patient tissue and…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Shariah compliance data provided by Zoya. Charting by TradingView.
Last updated:
